Volpara Solutions has announced the addition of John Pavlidis to its board of directors. According to the recent company announcement, John Pavlidis brings more than 25 years of technical and executive management experience in the medical industry to his seat on the board of directors for Volpara Solutions.
Pavlidis currently serves on the boards of Clario Medical and DySIS Medical, and previously served on the board for U-Systems, a developer of automated breast ultrasound screening that was acquired by GE Healthcare in 2012. Most recently, Pavlidis was president and CEO of Estech, a developer of minimally invasive surgical cardiac ablation devices, until the company was acquired by AtriCure in 2013.
“Throughout my career, my goal has always been to improve [people’s] health and well-being by helping high-quality medical device companies succeed,” said Pavlidis. “I am honored to be joining Volpara Solutions to help this highly accomplished team drive adoption of its industry leading breast imaging density and quantitative breast imaging tools that are rapidly becoming the industry gold standard.”
Volpara Solutions develops breast imaging tools, including VolparaDensity, an FDA-cleared algorithm that automatically and objectively measures volumetric breast density. The company also offers an analytics program and VolparaDoseRT, which uses volumetric quantitative data for a patient-specific assessment of the mean glandular dose (MGD) per image.
For more details, please see the news release from Volpara Solutions.